We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Evotec and APEIRON Biologics build Pain Alliance


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec and APEIRON Biologics build Pain Alliance"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 
Evotec AG has announced that it has entered into a collaboration with Apeiron Biologics AG, to initially identify small molecule modulators of DREAM (Downstream Regulatory Element Antagonistic Modulator), a novel target involved in perception of various pain mechanisms. Further projects will be evaluated to potentially expand this cooperation in due course.

Evotec will apply, in a first instance, its expertise in cellular assay development with opportunities for the project to rapidly move into hit identification and beyond.

Dr Hans Loibner, Chief Executive Officer at Apeiron Biologics, commented: “Combining our two companies’ skills is an excellent way to move forward with this innovative and promising project. We have worked with Evotec in the past and continue to be impressed by the quality of the work performed there.”

Dr Werner Lanthaler, Chief Executive Officer at Evotec stated: “Apeiron is certainly one of the most exciting young biotech companies in Europe. We are happy that through the optimal use of R&D outsourcing Evotec can add value here.”
Advertisement